Inhibrx (INBX) Director Douglas Forsyth Receives 10,000-Unit Award

What Happened

• Douglas Forsyth, a director of Inhibrx Biosciences, was granted 10,000 derivative units (reported as an "A" award) on 2026-06-03. The award shows an acquisition price of $0.00 (total reported value $0), and the instruments are not reported as common shares until vested/exercised. This Form 4 is an amended filing restating the original June 4, 2026 report to correct the number of options granted.

Key Details

• Transaction date: 2026-06-03
• Transaction type: Award/grant of derivative securities (code A)
• Quantity and price: 10,000 units @ $0.00 (reported value $0)
• Vesting/exercise: Fully exercisable on 2027-06-03, subject to continued service (footnote)
• Shares owned after transaction: Not disclosed in this filing
• Filing: Amended Form 4 filed 2026-09-18 to correct an administrative error from the original June 4, 2026 filing

Context

• These are derivative awards (options/units) that do not convert to voting shares until exercisable/vested; there was no immediate sale or cash exercise reported. Director awards like this are commonly part of compensation and do not by themselves indicate a buy/sell market view. The amendment simply corrects the reported grant quantity.